Claims

1. A method for the production of bispecific antibody construct for FcγRIII and CD30 comprising an amino acid sequence as set forth in SEQ ID NO:13, the method comprising the following steps

   (a) chromatographically capturing the antibody construct from a solution;
   (b) eluting the antibody construct from the capture matrix;
   (c) reducing the pH in the solution of the eluted antibody construct to low pH in a range of pH 3.5 to 3.9 pH and incubating the antibody construct under these conditions for at least 40h at a temperature of 2°C to 12°C or 15°C to 25°C;
   (d) neutralizing to a pH in the range of pH 4.5 to pH 8.0.

2. The method according to claim 1, wherein the antibody construct is incubated in step (c) for at least 48h.

3. The method according to any of claim 1 or 2, wherein the chromatographic capturing method in step (a) is selected form the group consisting of a protein L chromatography, an anion exchange chromatography (AEX), a cation exchange chromatography (CEX), a hydrophobic interaction chromatography (HIC) or a mixed mode chromatography (MMC).

4. The method according to any one of claims 1 to 3, wherein the method further comprises the additional steps:

   (e) capturing the antibody construct from the solution by at least one chromatographic method selected from the group consisting of an anion exchange chromatography (AEX), a cation exchange chromatography (CEX), a hydrophobic interaction chromatography (HIC) or a mixed mode chromatography (MMC).

5. The method according to any one of claims 1 to 4, wherein the elution of the antibody construct in step (b) is performed using a buffer selected from the group consisting of buffers comprising sodium acetate / acetic acid, sodium formiate /formic acid, sodium citrate / citric acid, and sodium succinate / succinic acid.

6. The method according to any one of claims 1 to 5, wherein the antibody construct is formulated as a pharmaceutical composition in a step (f).

7. The method according to claim 6 for formulating a pharmaceutical composition for the treatment or amelioration of a $CD30^+$ proliferative disease or a tumorous disease.